Eli Lilly therapeutic shows potential in thyroid cancer
The first randomised trial comparing efficacy of a highly selective…
The first randomised trial comparing efficacy of a highly selective RET-kinase inhibitor with multikinase inhibitors (MKIs) in advanced medullary thyroid cancer (MTC) has delivered promising results.